Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Agnus Castus
Generic Name
Agnus Castus
Active Ingredient
Chaste TreeCategory
Androgen [EPC]
Variants
29
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 30 [hp_C]/1 | PELLET | ORAL | 37662-3466 |
| 200 [hp_C]/1 | PELLET | ORAL | 37662-3468 |
| 10 [hp_M]/1 | PELLET | ORAL | 37662-3471 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Agnus Castus, you must consult a qualified healthcare professional.
| 1 [hp_X]/mL | LIQUID | ORAL | 15631-2562 |
| 12 [hp_C]/1 | PELLET | ORAL | 37662-3465 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-3470 |
| 6 [hp_C]/1 | PELLET | ORAL | 63545-146 |
| 100 [hp_C]/1 | PELLET | ORAL | 63545-777 |
| 200 [hp_C]/1 | PELLET | ORAL | 63545-778 |
| 500 [hp_C]/1 | PELLET | ORAL | 63545-779 |
| 1 [hp_M]/1 | PELLET | ORAL | 63545-780 |
| 1 [hp_X]/1 | PELLET | ORAL | 15631-0011 |
+ 5 more variants
Detailed information about Agnus Castus
Chaste Tree (Vitex agnus-castus) is a botanical extract classified as an Androgen [EPC] and hormonal modulator. It is primarily utilized in clinical settings to manage premenstrual syndrome (PMS) and menstrual irregularities by influencing prolactin levels and neurotransmitter activity.
Dosage for Chaste Tree varies significantly based on the formulation and the specific condition being treated. Because Chaste Tree works by modulating the endocrine system, it does not provide immediate relief; therapeutic effects often require 3 to 6 months of consistent use.
Chaste Tree is not recommended for use in children or adolescents under the age of 18. The endocrine systems of children are still developing, and introducing a potent hormonal modulator like Chaste Tree could theoretically interfere with normal pubertal development. There are no adequate clinical trials establishing the safety or efficacy of Chaste Tree in the pediatric population.
There is limited data regarding the use of Chaste Tree in patients with kidney disease. Since approximately 60% of its metabolites are excreted renally, caution is advised. Patients with Stage 3 or higher chronic kidney disease (CKD) should consult a specialist before use, as dose reductions may be necessary to prevent accumulation.
Because Chaste Tree is metabolized by the liver (specifically via the CYP450 system), patients with hepatic insufficiency (e.g., cirrhosis, hepatitis) may experience increased systemic exposure. Healthcare providers may suggest a lower starting dose or avoid use entirely in cases of severe liver failure.
Chaste Tree is generally not indicated for post-menopausal women unless specifically used for hormone-related symptoms. In elderly patients, the risk of interactions with other medications (polypharmacy) is higher. A thorough review of the patient's medication profile is required before initiation.
To achieve the best clinical outcomes, patients should adhere to the following guidelines:
If you miss a dose of Chaste Tree, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to make up for a missed one, as this may increase the risk of gastrointestinal side effects.
Acute toxicity from Chaste Tree is rare. However, a significant overdose may manifest as:
In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on gastrointestinal decontamination and symptom management.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as sudden cessation can lead to a 'rebound' increase in prolactin levels and a return of symptoms.
While Chaste Tree is generally well-tolerated, some patients may experience mild adverse reactions, particularly during the first few weeks of therapy as the body adjusts to hormonal shifts. Common side effects include:
Chaste Tree is a potent pharmacological agent despite its botanical origin. It should be treated with the same caution as any hormone-modulating drug. Patients must be aware that Chaste Tree can significantly alter the results of endocrine function tests and may mask underlying pathologies, such as pituitary tumors (prolactinomas). Always inform any specialist you visit that you are taking Chaste Tree.
As of 2026, there are no FDA black box warnings for Chaste Tree. It is important to note that Chaste Tree is primarily marketed as a dietary supplement in the U.S., and therefore, it does not undergo the same rigorous FDA labeling requirements as pharmaceutical drugs. However, clinical monographs from the European Medicines Agency (EMA) provide extensive safety data that patients should consider.
Certain medications must NEVER be used in combination with Chaste Tree due to the risk of severe adverse effects or complete neutralization of drug efficacy:
In the following conditions, Chaste Tree must NEVER be used because the risks far outweigh any potential benefits:
FDA Category: Not Assigned (Herbal). Chaste Tree is generally considered unsafe during pregnancy. Clinical data suggests that its effects on the pituitary-ovarian axis could disrupt the hormonal signaling necessary for the maintenance of the uterine lining. Furthermore, its Androgen Receptor Agonists [MoA] properties could theoretically affect the development of a male fetus. If you discover you are pregnant while taking Chaste Tree, discontinue use immediately and contact your obstetrician.
Chaste Tree is traditionally known as an 'antigalactagogue,' meaning it suppresses milk production. This occurs because the extract inhibits prolactin, the primary hormone responsible for lactation. While some traditional uses suggest low doses might increase milk, modern clinical pharmacology warns against its use during breastfeeding due to the high risk of reducing milk supply and the lack of safety data regarding the passage of its constituents into breast milk.
Chaste Tree (Vitex agnus-castus) operates through a complex, multi-receptor pathway. The primary molecular targets are the Dopamine D2 receptors located in the lactotroph cells of the anterior pituitary gland. The diterpenes in the extract (e.g., rotundifuran) bind to these receptors, mimicking the action of dopamine and subsequently inhibiting the secretion of prolactin. This is the 'Dopaminergic Effect.'
Additionally, Chaste Tree acts as a selective estrogen receptor modulator (SERM). It has a higher affinity for ER-beta receptors than ER-alpha receptors. This selectivity may explain why it can have beneficial effects on the breast and uterus without the same risks as pure estrogen. It also interacts with mu- and kappa-opioid receptors, which modulates the release of beta-endorphins, contributing to its analgesic and mood-stabilizing effects.
Common questions about Agnus Castus
Chaste Tree is primarily used in clinical settings to treat symptoms of premenstrual syndrome (PMS), including breast tenderness, bloating, and mood swings. It is also frequently utilized to manage menstrual irregularities, such as infrequent or frequent periods, by helping to balance the body's progesterone and estrogen levels. Some healthcare providers may recommend it for mild hyperprolactinemia (elevated prolactin) or as an adjunctive treatment for hormonal acne. Additionally, it has a history of use in treating infertility related to luteal phase defects. Always consult a doctor to ensure Chaste Tree is appropriate for your specific hormonal profile.
The most common side effects reported by patients taking Chaste Tree include gastrointestinal issues such as nausea, stomach cramps, and mild diarrhea. Some individuals also experience transient headaches, dizziness, or changes in their menstrual flow during the first few months of use. Acne flare-ups can occur initially due to shifts in androgen levels, though this often resolves with continued use. While generally mild, these side effects should be monitored, and any persistent or worsening symptoms should be reported to a healthcare provider. Taking the supplement with food may help mitigate stomach-related upset.
There are no known direct, dangerous chemical interactions between Chaste Tree and alcohol; however, caution is still advised. Alcohol can exacerbate common side effects of Chaste Tree, such as dizziness and gastrointestinal upset, potentially making the treatment less tolerable. More importantly, alcohol consumption can disrupt the endocrine system and hormonal balance, which may counteract the therapeutic goals of taking Chaste Tree. For the best clinical results, it is recommended to limit or avoid alcohol while attempting to regulate your menstrual cycle or treat PMS. Always discuss your lifestyle habits with your doctor when starting a new supplement.
No, Chaste Tree is considered unsafe and is strictly contraindicated during pregnancy. Because it acts as a potent hormonal modulator that influences the pituitary gland and inhibits prolactin, it could potentially interfere with the delicate hormonal environment necessary to maintain a pregnancy. There is also a theoretical risk that it could cause uterine contractions or affect the hormonal development of the fetus. If you are planning to become pregnant, you should discuss with your doctor when to stop taking Chaste Tree. If you discover you are pregnant while taking it, discontinue use immediately and seek medical advice.
Chaste Tree is not a fast-acting medication and requires a 'loading period' to effectively shift the body's hormonal baseline. Most clinical studies indicate that it takes at least two to three full menstrual cycles (approximately 8 to 12 weeks) of consistent daily use before a significant reduction in symptoms like PMS or breast pain is noticed. For conditions like infertility or chronic cycle irregularity, it may take up to six months to see the full therapeutic benefit. Patients are encouraged to be patient and maintain a consistent dosing schedule, as skipping doses can delay the onset of the drug's effects.
While Chaste Tree is not addictive, stopping it suddenly after long-term use may cause a 'rebound effect' where symptoms return, sometimes more intensely than before. This happens because the pituitary gland must readjust to the absence of the extract's dopaminergic influence, which can lead to a sudden spike in prolactin levels. To avoid a return of PMS or menstrual irregularities, it is often better to gradually taper the dose over several weeks under the guidance of a healthcare provider. If you experience any severe return of symptoms after stopping, consult your doctor to discuss a management plan.
If you miss a dose of Chaste Tree, you should take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed one and continue with your regular routine. It is important not to take two doses at once to make up for a missed one, as this can increase the likelihood of experiencing side effects like nausea or headache. Maintaining a consistent daily schedule, such as taking it at the same time every morning, is crucial for keeping hormone levels stable. If you find yourself frequently forgetting doses, consider using a pill organizer or a reminder app.
Weight gain is not a common side effect of Chaste Tree, but it has been reported by a small number of users in clinical trials and post-marketing surveillance. This effect is likely due to the supplement's influence on progesterone and estrogen, which can affect fluid retention and the way the body stores fat. In many cases, Chaste Tree actually helps *reduce* the bloating and water weight associated with PMS, leading to a perceived weight loss. If you notice significant or rapid weight gain while taking Chaste Tree, it is important to discuss this with your healthcare provider to rule out other underlying causes or metabolic changes.
Chaste Tree has several significant drug interactions that must be considered before starting therapy. It can interfere with the effectiveness of oral contraceptives (birth control pills) and hormone replacement therapy (HRT) by competing for the same receptors. It also interacts with medications that affect dopamine, such as antipsychotics (haloperidol) and drugs for Parkinson's disease (bromocriptine), potentially worsening psychiatric symptoms or causing movement disorders. Because of these risks, you must provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and other herbal supplements you are currently taking before starting Chaste Tree.
Chaste Tree is not a prescription drug in the United States, so the term 'generic' does not apply in the traditional pharmaceutical sense. Instead, it is available as a dietary supplement from numerous manufacturers under its botanical name, *Vitex agnus-castus*. While this means it is widely available and generally affordable, it also means that the quality and concentration of active ingredients can vary significantly between brands. To ensure you are getting a high-quality product, look for 'standardized extracts' that specify the amount of agnuside or casticin on the label. Consult your pharmacist for recommendations on reputable brands that follow Good Manufacturing Practices (GMP).
> Warning: Stop taking Chaste Tree and call your doctor immediately if you experience any of the following serious symptoms:
Data on the continuous use of Chaste Tree for more than one year is limited. Potential long-term effects may include:
No FDA black box warnings currently exist for Chaste Tree. However, the FDA does not evaluate herbal supplements for safety and efficacy in the same manner as prescription drugs. Healthcare providers emphasize that the lack of a black box warning does not imply the absence of risk, particularly for patients with hormone-sensitive cancers.
Report any unusual symptoms or persistent side effects to your healthcare provider. Keeping a 'symptom diary' can help your doctor determine if the side effects are related to the medication or your underlying condition.
Patients taking Chaste Tree for more than three months may require the following monitoring:
Chaste Tree may cause dizziness or mild sedation in some individuals. Until you know how Chaste Tree affects you, use caution when driving, operating heavy machinery, or performing tasks that require full mental alertness. If you experience significant dizziness, discontinue use and consult your doctor.
There is no known direct chemical interaction between Chaste Tree and alcohol. However, alcohol can worsen the gastrointestinal side effects and dizziness associated with Chaste Tree. Furthermore, alcohol can disrupt the very hormonal balance that Chaste Tree is intended to correct. It is generally advised to limit alcohol consumption during therapy.
Chaste Tree should not be stopped abruptly if it has been used for a long period. Tapering the dose over 2 to 4 weeks may help prevent a rebound increase in prolactin, which could cause a sudden return of PMS symptoms or breast pain. Discuss a discontinuation plan with your healthcare provider.
> Important: Discuss all your medical conditions, especially any history of cancer or psychiatric illness, with your healthcare provider before starting Chaste Tree. A full hormonal panel is often recommended before beginning therapy.
Chaste Tree can significantly alter the results of the following laboratory tests:
For each major interaction, the management strategy usually involves avoiding the combination or performing frequent blood tests to monitor hormone levels and drug efficacy.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A 'natural' product like Chaste Tree can have powerful interactions with modern medicine.
Conditions requiring a careful risk-benefit analysis and close medical supervision include:
Patients with known allergies to the following may be at higher risk for a reaction to Chaste Tree:
> Important: Your healthcare provider will evaluate your complete medical history, including any family history of hormone-related cancers, before determining if Chaste Tree is a safe option for you.
Chaste Tree is not approved for use in children. The safety and efficacy have not been established in patients under the age of 18. There is significant concern that the use of hormonal modulators in pre-pubescent or adolescent children could lead to permanent alterations in the hypothalamic-pituitary-gonadal (HPG) axis, affecting future fertility and growth.
In women over 65, Chaste Tree is rarely indicated as the primary hormonal issues it treats (PMS, menstrual cycles) are no longer present. In this population, the risk of side effects like dizziness and tachycardia is higher. Furthermore, elderly patients are more likely to be taking medications for cardiovascular or neurological conditions that could interact with Chaste Tree. Renal clearance is also naturally reduced in the elderly, which may necessitate lower doses if use is deemed necessary.
For patients with a Glomerular Filtration Rate (GFR) below 60 mL/min/1.73m², Chaste Tree should be used with caution. While there are no specific dose-adjustment tables, the 60% renal excretion rate of its metabolites suggests that accumulation could occur. Patients on dialysis should avoid Chaste Tree as its clearance via hemodialysis is unknown.
Patients with Child-Pugh Class B or C hepatic impairment should avoid Chaste Tree. The liver is the primary site for the metabolism of the diterpenes and flavonoids found in the extract. Reduced hepatic function can lead to significantly elevated plasma concentrations, increasing the risk of serious side effects like hepatotoxicity or severe hormonal disruption.
> Important: Special populations, particularly pregnant women and those with organ impairment, require individualized medical assessment. Never start an herbal supplement in these groups without professional consultation.
| Parameter | Value |
|---|---|
| Bioavailability | Moderate (Estimated 30-50%) |
| Protein Binding | 60-80% (primarily albumin) |
| Half-life | 1.5 - 3 hours (active diterpenes) |
| Tmax | 1 - 2 hours |
| Metabolism | Hepatic (CYP3A4 involvement suspected) |
| Excretion | Renal 60%, Fecal 40% |
Chaste Tree is classified as an Androgen [EPC], Estrogen [EPC], and Progesterone [EPC] modulator. Within the therapeutic hierarchy, it is considered a Phytotherapeutic Gonadotropin Inhibitor. It is related to other hormonal modulators like Black Cohosh (Actaea racemosa) and Red Clover (Trifolium pratense), though its dopaminergic mechanism is unique among these botanical agents.